Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 6/20 | 0.32 |
| ▸ | PARP1 | P09874 | 6/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697830 | 0.79 | KDM4E (0.43) | — | |
| SCHEMBL19950935 | 0.70 | SSTR4 (0.49) | TNKSPARP1TNKS2MAP3K5 | |
| SCHEMBL4274220 | 0.68 | APP (0.36) | CYP11B1CYP11B2MAP3K5 | |
| SCHEMBL698672 | 0.68 | PIK3CG (0.46) | MAP3K5 | |
| SCHEMBL24975703 | 0.62 | TNKS (0.41) | CYP11B1CYP11B2TNKSPARP1TNKS2 | |
| SCHEMBL251386 | 0.62 | SCN5A (0.38) | CYP11B1CYP11B2TNKSPARP1TNKS2 | |
| SCHEMBL196799 | 0.62 | MEN1 (0.48) | TNKSPARP1TNKS2 | |
| SCHEMBL4435717 | 0.61 | HSD11B1 (0.36) | — | |
| SCHEMBL24975699 | 0.61 | TNKS (0.37) | CYP11B1CYP11B2TNKSPARP1TNKS2 | |
| SCHEMBL4318445 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | claimed |
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | disclosed |
| EP-2040703-A2 | DERIVATIVES OF 2-BENZOYL-IMIDAZOPYRIDINES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003854-A2 | DERIVATIVES OF 2-BENZOYL-IMIDAZOPYRIDINES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | NR4A2, NR4A3, NCOR1 | SCN10A 1507/4885CYP11B1 962/4885CYP11B2 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.